The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

This year's headlines on respiratory syncytial virus (RSV) focused largely on the relatively new vaccines -- including a new ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Respiratory illnesses like the flu and COVID-19 spread more commonly in the fall and winter months ahead, and doctors in ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Dr. Kerry-Anne Perkins, a new mom and board-certified OB-GYN shares what parents need to know about RSV and more.

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...